FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
EPL Consensus Forecast
No. of reports in last year
5
No. of analysts
3
Average Consensus Forecast
295.2
Consensus Potential
32.72%
EPL Price Target Potential
| Brokerage | Target | Potential |
|---|---|---|
| Motilal Oswal | 285 | 30.88% |
| CD Equisearch | 263 | 25.10% |
| ICICIdirect.com | 275 | 28.36% |
EPL Ratings
Long term EPL rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
3.8/5 (4 Ratings)
5 EPL share price target reports by brokerages below. See what is analyst's view on EPL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
EPL Share Price Target
EPL Share Price Target - Broker Reports - 2021
Motilal Oswal
11-Nov-21
Price @ Call: 221
Target: 285
BUY
CD Equisearch
30-Sep-21
Price @ Call: 242
Target: 263
HOLD
ICICIdirect.com
30-Jul-21
Price @ Call: 246.15
Target: 275
HOLD
Motilal Oswal
30-Jul-21
Price @ Call: 246.15
Target: 320
BUY
Motilal Oswal
3-Feb-21
Price @ Call: 215.25
Target: 333
BUY
EPL Share Price Target - Broker Reports - 2020
Kotak Securities
13-Nov-20
Price @ Call: 256.2
Target: 265
ADD
Ashika Stock Broking
1-Oct-20
Price @ Call: 250.65
Target: 290
BUY
Reliance Securities
28-Sep-20
Price @ Call: 252.71
Target: 325
BUY
Kotak Securities
31-Jul-20
Price @ Call: 231.81
Target: 216
ADD
Essel’s continued focus on improvement in operating performance across the region has helped the company to maintain its EBITDA margin ~20%. The company reported improvement in operational performance due to better traction in Europe and EAP. The company captialised the opportunities by launching timely product, which supported the revenue growth and will continue to aid the performance in the coming quarters as well. We expect traction in the personal care segment to continue, driven by increasing penetration of laminated tubes in the end user industry will help the company to maintain EBITDA margin in the range of 20-21%. Prudent capex policy and improvement in operating efficiency, we expect net debt to decline further. We continue to remain positive on the stock given the strong business model. Factoring 1QFY21 performance, we have marginally revised our estimates higher to Rs7.2 (Earlier Rs6.9) and Rs9.3 (earlier Rs8.9) for FY21E and FY22E, respectively. At current valuation the stock is trading at 28.3x/22.1x FY21E/FY22E earnings. Despite the macro challenges and the impact of COVID-19, strong performance indicates management’s focus to increase its market share with the current customer and the addition of a new customer augur well for the company. We expect the stock to trade at a premium to its historical average, as higher share of personal care will drive the earnings coupled with improving RoCE. However, given the limited upside, we recommend ADD (earlier REDUCE), with a revised target price of Rs216 (earlier Rs189).
Kotak Securities
26-May-20
Price @ Call: 169.85
Target: 180
ADD
Essel’s continued focus on improvement in operating performance across the region has helped the company to maintain its EBITDA margin ~20%. The company reported improvement in operational performance in the last couple of quarters due to better traction in Europe. However, due to COVID-19 personal care demand across the region is expected to remain tepid and would weigh on overall performance. But, the launch of new product and recovery in China, would largely offset the impact. Though in the near term, we might see some pressure on personal care segment volume, however the long term story remains intact, driven by increasing penetration of laminated tubes in the end user industry. Prudent capex policy and improvement in operating efficiency, we expect net debt to decline further. We continue to remain positive on the stock given the strong business model. At current valuation of 24.9x/19.2x FY21E/FY22E earnings, the stock offers limited upside. Hence we recommend ADD, with an unchanged target price of Rs180.
Motilal Oswal
4-Mar-20
Price @ Call: 168.78
Target: 210
BUY
WeestimateaCAGRof8%inrevenueand20%inPAToverFY19-22,drivenby 11% revenue CAGR in the Americas, 5% in EAP, 3% in AMESA and 15% in Europe. We value the stock at 20x FY22E EPS of INR10.5, arriving at a target price of INR210. We initiate coverage with a Buy rating.
EPL Share Price Target - Broker Reports - 2019
Kotak Securities
11-Nov-19
Price @ Call: 125.39
Target: 154
BUY
Key things to watch out for would be the sustainability of the numbers in the coming quarters. Factoring 2QFY20 performance, we have revised our earnings and at CMP, the stock is 16.8x/13.7x FY20E/FY21E, revised earnings, which is discount to its last 5 years median. We now recommend BUY (earlier ADD), with a revised target price of Rs154 (earlier Rs128), valuing at 18x (earlier 17x) as we believe, with a large capex behind and strong FCF generation in the coming years, it will return excess cash to shareholders and this should improve its return ratios.
Kotak Securities
16-Aug-19
Price @ Call: 94.55
Target: 117
ADD
We believe re-rating of earnings multiple seems to be limited. Given the fall in the stock price since our last update in the month of July (rating Reduce), we now upgrade the stock to ADD, with a revised target price of Rs117 (earlier Rs127), valuing at 17x FY21E earnings, considering the slowdown in India and China. At CMP, the stock is trading at 17.3x/15.2x FY20E/FY21E earnings.
Kotak Securities
16-Jul-19
Price @ Call: 130
Target: 127
REDUCE
Increasing presence in emerging markets and further penetration into non-oral category is expected to support the earnings CAGR of 8% during the FY19-FY21E period. We believe potential for re-rating of earnings multiple seems to be limited, hence, we continue to maintain Reduce on the stock, with a revised target price of Rs127 (earlier Rs130), valuing at 17x FY21E earnings. At CMP, the stock is trading at 20x/17.3x FY20E/FY21E earnings.
CD Equisearch
4-Jul-19
Price @ Call: 130.5
Target: 155
ACCUMULATE
The stock currently trades at 19.1x FY19e EPS of Rs 6.80 and 16.8x FY20e EPS of Rs 7.76. Growth will be invigorated by burgeoning demand in the packaging industry, better capacity utilization at the company’s Europe plants- relocation of Russian unit to a new location for future growth opportunities & setting up of a custom built factory near Guwahati, Assam. However, the disruption caused by the prospering e-commerce business indirectly exposes EPL to vagaries of demand. Weighing odds, we advise buying the stock with the revised target price of Rs 155 (previous target Rs 140 (adjusted for bonus)) based on 20x FY21e EPS of Rs 7.76 over a period of 9-12 months.
Kotak Securities
9-May-19
Price @ Call: 133.5
Target: 130
REDUCE
ICICIdirect.com
23-Apr-19
Price @ Call: 133
Target: 136
HOLD
EPL is a global leader in laminated tubes selling ~7 billion tubes across 10 countries. EPL's clientele includes marquee global brands (Colgate, HUL, etc) in the oral care, beauty, cosmetics and pharmaceutical industries. Increasing presence in emerging markets and further penetration in the fast growing beauty, cosmetics and pharmaceutical segments is expected to accelerate growth, going forward. We believe revenue, earnings CAGR of ~12%, ~13% in FY18- 21E would largely led by strong performance in emerging markets. We believe a demand recovery in the Amesa and Europe region will be a key trigger for future growth. With a target market cap, the deal is valued at 20xFY20E, 17xFY21E earnings and 8xFY20E, 7xFY21E EBITDA, respectively. We believe the stock would hover around the deal price.
Geojit Financial Services
5-Mar-19
Price @ Call: 113.04
Target: 121
HOLD
We model revenue and adj.PAT CAGR of 12% and 15%, respectively over FY18-21E to factor in recovery in India business, improved utilization in European region and increased contribution of non-oral care segment. Hence, we maintain ‘HOLD’ rating on the stock with a revised rolled over target price of Rs121 based on 14x FY21E EPS.
ICICIdirect.com
28-Jan-19
Price @ Call: 102.15
Target: 120
HOLD
EPL Share Price Target - Broker Reports - 2018
Kotak Securities
8-Aug-18
Price @ Call: 105.1
Target: 140
BUY
ICICIdirect.com
30-Jul-18
Price @ Call: 106.22
Target: 115
HOLD
Edelweiss
27-Jul-18
Price @ Call: 107.89
Target: 135
BUY
CD Equisearch
18-Jul-18
Price @ Call: 105.5
Target: 140
BUY
ICICIdirect.com
30-Apr-18
Price @ Call: 134.61
Target: 150
HOLD
Edelweiss
3-May-18
Price @ Call: 131.7
Target: 157
BUY
Edelweiss
6-Feb-18
Price @ Call: 140
Target: 158.5
BUY
ICICIdirect.com
5-Feb-18
Price @ Call: 135
Target: 150
HOLD
Geojit Financial Services
10-Jan-18
Price @ Call: 148.25
Target: 170.5
BUY
EPL Share Price Target - Broker Reports - 2017
CD Equisearch
22-Dec-17
Price @ Call: 145.28
Target: 172
ACCUMULATE
ICICIdirect.com
9-Nov-17
Price @ Call: 143.95
Target: 155
HOLD
Edelweiss
18-Aug-17
Price @ Call: 131.5
Target: 150
BUY
ICICIdirect.com
14-Aug-17
Price @ Call: 125.18
Target: 135
HOLD
Centrum
1-Jun-17
Price @ Call: 129
Target: 158
BUY
Edelweiss
25-May-17
Price @ Call: 129.5
Target: 150.5
BUY
IIFL
8-May-17
Price @ Call: 129.5
Target: 160
BUY
CD Equisearch
21-Apr-17
Price @ Call: 117
Target: 141.5
BUY
Centrum
8-Feb-17
Price @ Call: 246
Target: 293
BUY
Axis Direct
6-Feb-17
Price @ Call: 247
Target: 272
BUY
ICICIdirect.com
6-Feb-17
Price @ Call: 248
Target: 270
BUY
Centrum
16-Jan-17
Price @ Call: 246.03
Target: 293
BUY
EPL Share Price Target - Broker Reports - 2016
Axis Direct
3-Nov-16
Price @ Call: 246
Target: 275
BUY
Motilal Oswal
2-Sep-16
Price @ Call: 212.2
Target: 230
NEUTRAL
CD Equisearch
21-Sep-16
Price @ Call: 224
Target: 298
BUY
Way2Wealth
7-Sep-16
Price @ Call: 215.62
Target: 213
REDUCE
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
EPL Peer Stocks - Share Price Targets
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.